JP2020520986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520986A5 JP2020520986A5 JP2019565425A JP2019565425A JP2020520986A5 JP 2020520986 A5 JP2020520986 A5 JP 2020520986A5 JP 2019565425 A JP2019565425 A JP 2019565425A JP 2019565425 A JP2019565425 A JP 2019565425A JP 2020520986 A5 JP2020520986 A5 JP 2020520986A5
- Authority
- JP
- Japan
- Prior art keywords
- drug composition
- substituted
- lung infection
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- 208000032376 Lung infection Diseases 0.000 claims 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 230000001580 bacterial effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- -1 amino, substituted amino Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229960003085 meticillin Drugs 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000033 alkoxyamino group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000004470 heterocyclooxy group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000005255 oxyaminoacyl group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000005296 thioaryloxy group Chemical group 0.000 claims 1
- 125000005404 thioheteroaryloxy group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 0 C*NC(C)(CC(OC(C1O)C(Oc(c(Oc(ccc(C(*)C(C(NC(C(*)=O)c2cc(O)c(*)c(O)c2-c2cc(C3NC(C4NC(C(CC(N)=O)NC(C(C(c(cc5)c6)O)NC(C(CC(C)C)NC)=O)=O)=O)=O)ccc2O)=O)NC3=O)c2)c2Cl)cc4c2)c2Oc5c6Cl)OC(CO)C1O)OC1C)C1O Chemical compound C*NC(C)(CC(OC(C1O)C(Oc(c(Oc(ccc(C(*)C(C(NC(C(*)=O)c2cc(O)c(*)c(O)c2-c2cc(C3NC(C4NC(C(CC(N)=O)NC(C(C(c(cc5)c6)O)NC(C(CC(C)C)NC)=O)=O)=O)=O)ccc2O)=O)NC3=O)c2)c2Cl)cc4c2)c2Oc5c6Cl)OC(CO)C1O)OC1C)C1O 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509378P | 2017-05-22 | 2017-05-22 | |
| US62/509,378 | 2017-05-22 | ||
| US201762518280P | 2017-06-12 | 2017-06-12 | |
| US62/518,280 | 2017-06-12 | ||
| US201762560413P | 2017-09-19 | 2017-09-19 | |
| US62/560,413 | 2017-09-19 | ||
| PCT/US2018/033953 WO2018217800A1 (en) | 2017-05-22 | 2018-05-22 | Glycopeptide derivative compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520986A JP2020520986A (ja) | 2020-07-16 |
| JP2020520986A5 true JP2020520986A5 (enExample) | 2021-07-26 |
| JP7165146B2 JP7165146B2 (ja) | 2022-11-02 |
Family
ID=64395938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565425A Active JP7165146B2 (ja) | 2017-05-22 | 2018-05-22 | グリコペプチド誘導体化合物およびそれらの使用 |
| JP2019565468A Active JP7210476B2 (ja) | 2017-05-22 | 2018-05-22 | リポ‐グリコペプチド可切断性誘導体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565468A Active JP7210476B2 (ja) | 2017-05-22 | 2018-05-22 | リポ‐グリコペプチド可切断性誘導体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200368312A1 (enExample) |
| EP (2) | EP3634464A4 (enExample) |
| JP (2) | JP7165146B2 (enExample) |
| KR (2) | KR102661790B1 (enExample) |
| CN (2) | CN110996984A (enExample) |
| AU (2) | AU2018271873B2 (enExample) |
| BR (2) | BR112019024472A2 (enExample) |
| CA (2) | CA3062567A1 (enExample) |
| GB (2) | GB2577420B (enExample) |
| IL (2) | IL270686B (enExample) |
| NZ (2) | NZ758836A (enExample) |
| WO (2) | WO2018217808A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| IL270686B (en) | 2017-05-22 | 2022-09-01 | Insmed Inc | Derivatives of glycopeptides and their uses |
| NL2023883B1 (en) * | 2019-09-24 | 2021-04-26 | Univ Leiden | Antibiotic compounds |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| US20240024411A1 (en) * | 2021-11-24 | 2024-01-25 | Cumberland Pharmaceuticals Inc. | Methods for the prevention or treatment of anthrax infection |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| IE873523L (en) * | 1986-12-30 | 1988-06-30 | Memorex Corp | Glycosylated glycopeptides |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| WO1999016420A1 (en) | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in nebulizers |
| DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
| US6518242B1 (en) * | 1998-02-20 | 2003-02-11 | Theravance, Inc. | Derivatives of glycopeptide antibacterial agents |
| AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| BRPI9914221B8 (pt) * | 1998-12-23 | 2021-05-25 | Advanced Medicine Inc | derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos |
| ATE331544T1 (de) | 1999-05-28 | 2006-07-15 | Nektar Therapeutics | Gerät und verfahren zur aerosolisierung einer pharmazeutischen pulverzusammensetzung |
| US6606992B1 (en) | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
| US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| WO2001057071A2 (en) | 2000-02-04 | 2001-08-09 | Advanced Medicine, Inc. | Glycopeptide derivatives having antibiotic activity |
| JP2003522197A (ja) | 2000-02-11 | 2003-07-22 | イーライ リリー アンド カンパニー | Ａ８２８４６グリコペプチドアナログの選択的ｎ−アシル化 |
| CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| AU2003287605A1 (en) | 2002-11-12 | 2004-06-03 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
| US7521418B2 (en) | 2003-05-27 | 2009-04-21 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| US20070185015A1 (en) * | 2005-02-28 | 2007-08-09 | Chiron Corporation and North China Pharmaceutical Corporation | Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity |
| US7632918B2 (en) * | 2005-02-28 | 2009-12-15 | Novartis Vaccines And Diagnostics, Inc. | Semi-synthetic glycopeptides with antibiotic activity |
| BRPI0817311A2 (pt) | 2007-09-25 | 2015-03-17 | Novartis Ag | Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina |
| US20090104257A1 (en) * | 2007-10-23 | 2009-04-23 | Xingong Li | Liposomal Vancomycin Formulations |
| KR20100109936A (ko) * | 2007-12-26 | 2010-10-11 | 리드 테라퓨틱스, 인크. | 항박테리아제로서의 신규한 반(半)-합성 글리코펩티드 |
| WO2010048340A2 (en) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
| US20120058198A1 (en) * | 2009-03-26 | 2012-03-08 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
| PT2424559T (pt) * | 2009-04-28 | 2024-04-30 | Melinta Therapeutics Llc | Métodos de tratamento de infeções bacterianas utilizando oritavancina |
| JP6012716B2 (ja) | 2011-05-19 | 2016-10-25 | サヴァラ，インク． | 乾燥粉末バンコマイシン組成物および関連する方法 |
| US9572774B2 (en) * | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
| EP2739289B1 (en) | 2011-08-05 | 2020-05-06 | The Scripps Research Institute | Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains |
| MX369828B (es) * | 2012-05-21 | 2019-11-22 | Insmed Inc | Sistemas para tratar infecciones pulmonares. |
| ES2743039T3 (es) * | 2012-11-29 | 2020-02-18 | Insmed Inc | Formulaciones de vancomicina estabilizada |
| GB201402267D0 (en) * | 2014-02-10 | 2014-03-26 | Cambridge Entpr Ltd | Antibacterial agents |
| CN105085636B (zh) * | 2014-05-19 | 2020-05-01 | 中国医学科学院药物研究所 | 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用 |
| US10577395B2 (en) | 2014-07-10 | 2020-03-03 | The Scripps Research Institute | N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin |
| CN107325159A (zh) | 2016-04-29 | 2017-11-07 | 中国科学院上海药物研究所 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
| WO2018008197A1 (ja) | 2016-07-07 | 2018-01-11 | 日東電工株式会社 | 反射層および蛍光体層付光半導体素子 |
| WO2018081797A1 (en) | 2016-10-31 | 2018-05-03 | The Scripps Research Institute | Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability |
| IL270686B (en) * | 2017-05-22 | 2022-09-01 | Insmed Inc | Derivatives of glycopeptides and their uses |
-
2018
- 2018-05-22 IL IL270686A patent/IL270686B/en unknown
- 2018-05-22 AU AU2018271873A patent/AU2018271873B2/en active Active
- 2018-05-22 KR KR1020197035485A patent/KR102661790B1/ko active Active
- 2018-05-22 NZ NZ758836A patent/NZ758836A/en unknown
- 2018-05-22 GB GB1917677.5A patent/GB2577420B/en active Active
- 2018-05-22 BR BR112019024472-7A patent/BR112019024472A2/pt not_active Application Discontinuation
- 2018-05-22 IL IL270685A patent/IL270685B/en unknown
- 2018-05-22 EP EP18805177.5A patent/EP3634464A4/en active Pending
- 2018-05-22 AU AU2018273887A patent/AU2018273887B2/en active Active
- 2018-05-22 US US16/615,232 patent/US20200368312A1/en not_active Abandoned
- 2018-05-22 JP JP2019565425A patent/JP7165146B2/ja active Active
- 2018-05-22 US US16/615,214 patent/US11071769B2/en not_active Expired - Fee Related
- 2018-05-22 CA CA3062567A patent/CA3062567A1/en active Pending
- 2018-05-22 NZ NZ758839A patent/NZ758839A/en unknown
- 2018-05-22 BR BR112019024549A patent/BR112019024549A2/pt not_active Application Discontinuation
- 2018-05-22 CN CN201880048300.3A patent/CN110996984A/zh active Pending
- 2018-05-22 JP JP2019565468A patent/JP7210476B2/ja active Active
- 2018-05-22 CN CN201880047233.3A patent/CN110891590B/zh active Active
- 2018-05-22 EP EP18805750.9A patent/EP3630154A4/en active Pending
- 2018-05-22 CA CA3062570A patent/CA3062570A1/en active Pending
- 2018-05-22 WO PCT/US2018/033963 patent/WO2018217808A1/en not_active Ceased
- 2018-05-22 KR KR1020197035481A patent/KR102661786B1/ko active Active
- 2018-05-22 WO PCT/US2018/033953 patent/WO2018217800A1/en not_active Ceased
- 2018-05-22 GB GB1917675.9A patent/GB2577419B/en active Active
-
2021
- 2021-06-10 US US17/344,322 patent/US11857597B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520986A5 (enExample) | ||
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| MX2020007633A (es) | Péptidos macrocíclicos contra acinetobacter baumannii. | |
| JP2016513688A5 (enExample) | ||
| JP2013537229A5 (enExample) | ||
| JP2016531871A5 (enExample) | ||
| JP2018524406A5 (enExample) | ||
| EA202090604A1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций | |
| CO2020013876A2 (es) | Nuevos derivados de quinolina | |
| MX2025003905A (es) | Tiosulfato de sodio anhidro y formulaciones de este | |
| JP2017502984A5 (enExample) | ||
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| MX2025004812A (es) | Compuestos heterociclicos con capacidad para activar el receptor sting | |
| ZA202301937B (en) | Compounds | |
| JP2020520987A5 (enExample) | ||
| BR0210667A (pt) | Derivados de oxazolidinonas como agentes antibacterianos | |
| CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения | |
| CY1110706T1 (el) | Αντιβακτηριδιακα παραγωγα κινολινης | |
| JP2018513193A5 (enExample) | ||
| JO2970B1 (en) | Quinoline antibacterial derivatives | |
| MX2020011980A (es) | Depsipéptidos endoparasiticidas. | |
| JP2021501783A5 (enExample) | ||
| JP2019517474A5 (enExample) |